125 related articles for article (PubMed ID: 30947577)
21. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.
Colosia A; Njue A; Trask PC; Olivares R; Khan S; Abbe A; Police R; Wang J; Ruiz-Soto R; Kaye JA; Awan F
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):343-355.e6. PubMed ID: 24768510
[TBL] [Abstract][Full Text] [Related]
22. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K; Chizuka A
Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant.
Qiao W; Zhao J; Xing Y; Wang C; Wang T
Leuk Lymphoma; 2014 Feb; 55(2):276-82. PubMed ID: 23617323
[TBL] [Abstract][Full Text] [Related]
24. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
[TBL] [Abstract][Full Text] [Related]
25. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
Viviani S; Camerini E; Bonfante V; Santoro A; Balzarotti M; Fornier M; Devizzi L; Verderio P; Valagussa P; Bonadonna G
Br J Cancer; 1998 Mar; 77(6):992-7. PubMed ID: 9528846
[TBL] [Abstract][Full Text] [Related]
26. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
[TBL] [Abstract][Full Text] [Related]
27. Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
Maurer MJ; Jakobsen LH; Mwangi R; Schmitz N; Farooq U; Flowers CR; de Nully Brown P; Thompson CA; Frederiksen H; Cunningham D; Jørgensen J; Poeschel V; Nowakowski G; Seymour JF; Merli F; Haioun C; Ghesquieres H; Ziepert M; Tilly H; Salles G; Shi Q; El-Galaly TC; Habermann TM
Am J Hematol; 2021 May; 96(5):599-605. PubMed ID: 33661547
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma.
Lu TX; Wu S; Cai DY; Hong TT; Zhang Y; Gao HQ; Hua HY; Wu XH
BMC Cancer; 2019 Jun; 19(1):553. PubMed ID: 31176361
[TBL] [Abstract][Full Text] [Related]
29. Prognostic importance of the soluble form of IL-2 receptorα (sIL-2Rα) and its relationship with surface expression of IL-2Rα (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases.
Hashimoto Y; Yokohama A; Saitoh A; Nakahashi H; Toyama K; Mitsui T; Koiso H; Saitoh T; Handa H; Uchiumi H; Jinbo T; Murayama K; Matsumoto M; Sawamura M; Karasawa M; Murakami H; Hirato J; Nojima Y; Kojima M; Tsukamoto N
J Clin Exp Hematop; 2013; 53(3):197-205. PubMed ID: 24369221
[TBL] [Abstract][Full Text] [Related]
30. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy.
Shirouchi Y; Nishimura N; Mishima Y; Ishihara Y; Asai H; Tamba M; Hirano M; Hirano K; Teramoto Y; Yoshida K; Takeuchi K; Terauchi T; Maruyama D
Sci Rep; 2023 Aug; 13(1):13713. PubMed ID: 37608029
[TBL] [Abstract][Full Text] [Related]
32. Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U).
Kitagawa J; Hara T; Tsurumi H; Goto N; Kanemura N; Yoshikawa T; Kasahara S; Yamada T; Sawada M; Takahashi T; Shimizu M; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2009 Jan; 135(1):53-9. PubMed ID: 18592269
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.
Armand P; Welch S; Kim HT; LaCasce AS; Jacobsen ED; Davids MS; Jacobson C; Fisher DC; Brown JR; Coughlin E; Freedman AS; Chen YB
Br J Haematol; 2013 Mar; 160(5):608-17. PubMed ID: 23278720
[TBL] [Abstract][Full Text] [Related]
34. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
[TBL] [Abstract][Full Text] [Related]
35. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
Wagner-Johnston ND; Goy A; Rodriguez MA; Ehmann WC; Hamlin PA; Radford J; Thieblemont C; Suh C; Sweetenham J; Huang Y; Sullivan ST; Vandendries ER; Gisselbrecht C
Leuk Lymphoma; 2015; 56(10):2863-9. PubMed ID: 25707288
[TBL] [Abstract][Full Text] [Related]
36. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
Porrata LF; Ristow K; Habermann TM; Witzig TE; Inwards DJ; Markovic SN
Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study.
Kim JW; Kim SW; Tada K; Fukuda T; Lee JH; Lee JJ; Kwon JH; Bang SM; Kim I; Yoon SS; Lee JS; Park S
Ann Hematol; 2014 Aug; 93(8):1345-51. PubMed ID: 24633661
[TBL] [Abstract][Full Text] [Related]
38. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
[TBL] [Abstract][Full Text] [Related]
40. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wong KK; Ch'ng ES; Loo SK; Husin A; Muruzabal MA; Møller MB; Pedersen LM; Pomposo MP; Gaafar A; Banham AH; Green TM; Lawrie CH
Exp Mol Pathol; 2015 Dec; 99(3):537-45. PubMed ID: 26341140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
